A combination image shows an injection pen of Zepbound, Eli Lilly's weight loss drug, and boxes of Wegovy, made by Novo Nordisk. REUTERS/Hollie Adams/Brendan McDermid/Combination/

(Reuters) -Telehealth company Mangoceuticals said on Thursday it has partnered with Eli Lilly and Novo Nordisk to sell the drugmakers' blockbuster weight-loss drugs through its platform.

Shares of Mangoceuticals surged 32% in premarket trading.

Mangoceuticals said it has launched MangoRx Direct and PeachesRx Direct programs, through which these branded GLP-1 medications will be made available.

Customers of these programs can access Lilly's weight-loss drug Zepbound through LillyDirect and Novo's drug Wegovy through NovoCare Pharmacy, the telehealth company said.

Lilly launched its direct-to-consumer website LillyDirect last year, while Novo started NovoCare Pharmacy in March this year.

(Reporting by Christy Santhosh in Bengaluru; Editing by Leroy Leo)